reports
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obe...
OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium MIAMI, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) today announced its participation in the 3rd Annual Piper Sandler Obesity Symposium being held virtually on June 26, 2025. Management will be participating in a fireside discussion moderated by Edward Tentoff, Managing Director, Senior Biotechnology Analyst. Investors can register for the symposium by contacting their Piper Sandler representative. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics ...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Gluc...
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisc...
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAM...
Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in a...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Adv...
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer ModeX’s promising immunology pipeline includes first-in class drugs with two assets in ongoing clinical trials and multiple pre-IND assets to enter clinical trials WESTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), to...
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcar...
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the Jefferies Healthcare Conference, to take place June 3 - 5, 2025, in New York. A webcast of the presentation will be available on June 5th at 8:10 AM EDT. The webcast will be available to watch and there will be a replay for approximately 90-days following the presentation on ...
OPKO Health to Participate in Two Upcoming Investor Conferences
OPKO Health to Participate in Two Upcoming Investor Conferences MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in two investor conferences over the coming weeks. H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will hold one-on-one meetings with investors and will participate in a fireside discussion at 9:00 a.m. Eastern time. Jefferies Global Healthcare Conference, June 3-5 at the Marriott Marquis in New York City. Management will hold one-on-one meet...
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results...
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL is...
- Jonathan Moreland
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XPL SOLITARIO ZINC
RGP RESOURCES CONNECTION INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
LPG DORIAN LPG
WHF WHITEFIELD
AMTX AEMETIS
GCBC GREENE COUNTY BANCORP INC.
JFR NUVEEN FLOATING RATE INCOME FUND
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
NHF NEXPOINT CREDIT STRATEGIES FUN
DOMO DOMO INCORPORATED
BCDA BIOCARDIA
PCB PACIFIC CITY FINANCIAL CORP
ASAN ASANA
PCVX VAXCYTE
WOOF PETCO HEALTH AND WELLNESS
NUVB NUVATION BIO INC (A)
CTGO CONTANGO ORE INC.
SMMT SUMMIT THERAPEUTICS INC
HUMA HUMACYTE INC
TCBX THIRD COAST BANCSHARES INC
PEPG PEPGEN INC
GLSI GREENWICH LIFESCIENCES INC
JMSB JOHN MARSHALL BANCORP INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
NMTC NEUROONE MEDICAL TECHNOLOGIES CORP
SSII SS INNOVATIONS INTERNATIONAL INC
CATX PERSPECTIVE THERAPEUTICS
DMA INC.
SUNS DESTRA MULTI ALTERNATIVE FUND
NUTX SUNRISE REALTY TRUST
AFCG NUTEX HEALTH INC
FTLF AFC GAMMA
INC.
FITLIFE BRANDS INC.
OPKO Health Reports First Quarter 2025 Business Highlights and Financi...
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReference). The transaction includes the sale of BioReference’s laboratory te...
OPKO Health to Report First Quarter 2025 Financial Results on April 30...
OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to p...
- Jonathan Moreland
OPK OPKO HEALTH INC.
OMI OWENS & MINOR INC.
NEOG NEOGEN CORPORATION
CVGW CALAVO GROWERS INC.
LPG DORIAN LPG
ADC AGREE REALTY CORPORATION
JFR NUVEEN FLOATING RATE INCOME FUND
JELD JELD-WEN HOLDING INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ASAN ASANA
PCVX VAXCYTE
UAN CVR PARTNERS LP
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
BTMD HAYMAKER ACQUISITION CORP III
TEAF ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GTE GRAN TIERRA ENERGY INC.
SBGI SINCLAIR INC
CVI CVR ENERGY
MIO INC.
NYC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
BATRK NEW YORK CITY REIT
ECF INC.
OS LIBERTY MEDIA CORPORATION
ELLSWORTH FUND LTD
OREGON STEEL MILLS INC
- Jonathan Moreland
TDOC TELADOC HEALTH INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
RDNT RADNET INC.
OPK OPKO HEALTH INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
AMTX AEMETIS
CNFR CONIFER HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
CMPX COMPASS THERAPEUTICS
NUVB INC.
HUMA NUVATION BIO INC (A)
BUKS HUMACYTE INC
GLSI BUTLER NATIONAL CORP
VANI GREENWICH LIFESCIENCES INC
GTE VIVANI MEDICAL INC
EVM GRAN TIERRA ENERGY INC.
EATON VANCE INSD CALIF MUN BD FD
OPKO Health Announces $100 Million Increase to its Existing Share Repu...
OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized an increase of $100 million to the Company’s existing common stock repurchase program, bringing the aggregate capacity of the program to $200 million. Approximately $41 million of OPKO’s common stock has been repurchased under the existing program since its authorization in July 2024. “We believe OPKO’s shares continue to be significantly undervalued and offer an attractive...
- Jonathan Moreland
ULTA ULTA BEAUTY INC
STAA STAAR SURGICAL CO.
SIGI SELECTIVE INSURANCE GROUP INC.
SIG SIGNET JEWELERS LIMITED
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PSEC PROSPECT CAPITAL CORPORATION
PEB PEBBLEBROOK HOTEL TRUST
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MTDR MATADOR RESOURCES COMPANY
MEI METHODE ELECTRONICS INC.
JCOM J2 GLOBAL INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HUN HUNTSMAN CORPORATION
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HSC
I3N HARSCO CORPORATION
FSS CHART INDUSTRIES INC.
EVH FEDERAL SIGNAL CORPORATION
ECPG EVOLENT HEALTH INC CLASS A
CMC ENCORE CAPITAL GROUP INC.
APPS COMMERCIAL METALS COMPANY
AMRC DIGITAL TURBINE
ADBE AMERESCO
HRTG ADOBE INC.
FMC HERITAGE INSURANCE HOLDINGS INC.
MAC FMC CORPORATION
LIVE MACERICH COMPANY
FLGT LIVE VENTURES
FCNCA FULGENT GENETICS
DMLP FIRST CITIZENS BANCSHARES INC. CLASS A
RCII DORCHESTER MINERALS L.P.
FTDR RENT-A-CENTER INC
NFE FRONTDOOR INC.
GRWG NEW FORTRESS ENERGY
PCB GROWGENERATION
CMPR PACIFIC CITY FINANCIAL CORP
RC CIMPRESS PLC
ACA GRUPO RADIO CENTRO S.A.B. DE C.V.
RZLT ARCOSA
ONEW REZOLUTE
PRLD INC.
FET ONEWATER MARINE
IMNM PRELUDE THERAPEUTICS
CMTG FORUM ENERGY TECHNOLOGIES
LYEL IMMUNOME
BTMD CLAROS MORTGAGE TRUST
IE INC.
EBC LYELL IMMUNOPHARMA INC
MODD HAYMAKER ACQUISITION CORP III
MRNA IVANHOE ELECTRIC INC
FG EASTERN BANKSHARES INC
MODULAR MEDICAL INC
MODERNA
INC.
F AND G ANNUITIES AND LIFE
INC.
- Jonathan Moreland
OPK OPKO HEALTH INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
SVRA SAVARA
PNBK PATRIOT NATIONAL BANCORP
FUND ROYCE FOCUS TRUST
WOOF INC.
UAN PETCO HEALTH AND WELLNESS
GAM CVR PARTNERS LP
CATX GENERAL DE ALQUILER DE MAQUINARIA
SUNS PERSPECTIVE THERAPEUTICS
AFCG INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
- Jonathan Moreland
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OPK OPKO HEALTH INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
FLWS 1-800-FLOWERS.COM CL A
RZLT REZOLUTE
VSCO INC.
TOI VICTORIA'S SECRET & CO
BLIN ONCOLOGY INSTITUTE INC (THE)
BNTC BRIDGELINE DIGITAL INC
FG BENITEC BIOPHARMA INC
CAUD F AND G ANNUITIES AND LIFE
INC.
COLLECTIVE AUDIENCE
INC.
FDA Issues Complete Response Letter for Etripamil for PSVT
FDA Issues Complete Response Letter for Etripamil for PSVT CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray, a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults. ...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
SRE SEMPRA ENERGY
PSEC PROSPECT CAPITAL CORPORATION
ORRF ORRSTOWN FINANCIAL SERVICES INC.
OPK OPKO HEALTH INC.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
HSC HARSCO CORPORATION
GOGO GOGO INC.
FRPT FRESHPET INC
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
CMCO COLUMBUS MCKINNON CORPORATION
MAC MACERICH COMPANY
PETS PETMED EXPRESS INC.
TREE LENDINGTREE INC.
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
FTHM FATHOM HOLDINGS
CLVT CLARIVATE PLC
LYEL LYELL IMMUNOPHARMA INC
FLNC FLUENCE ENERGY INC
HD HOME DEPOT
BTMD INC.
ECAT HAYMAKER ACQUISITION CORP III
BUKS BLACKROCK ESG CAP ALLOCATION TR
ONL BUTLER NATIONAL CORP
MLYS ORION OFFICE REIT INC
WEST MINERALYS THERAPEUTICS INC
SBGI WESTROCK COFFEE COMPANY LLC
DK SINCLAIR INC
CVI DELEK US HOLDINGS
SRBK INC.
GUTS CVR ENERGY
ADVM INC.
SUNS SR BANCORP INC
AFCG FRACTYL HEALTH INC
ADVERUM BIOTECHNOLOGIES INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the...
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present a moderated poster presentation at the , to be held March 29th to 31st, 2025 in Chicago, Illinois. “This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supr...
Opko Health Inc: 1 director
A director at Opko Health Inc bought 200,000 shares at 1.739USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.